K562 / K562-luc Orthotopic Mouse Model Service for Leukemia

The K562 / K562-luc orthotopic mouse model for leukemia engrafts a Philadelphia chromosome-positive human chronic myeloid leukemia line into the blood and bone marrow compartments of immunodeficient mice, where disseminated disease can be quantified non-invasively over time. Exclusively a preclinical CRO, Alfa Cytology delivers this model as a complete service, from authenticated K562 / K562-luc cell supply through intravenous or intraosseous inoculation, scheduled in vivo bioluminescence imaging, and terminal organ-level analysis.

Overview of K562 / K562-luc Orthotopic Mouse Model for Leukemia

K562 occupies a unique place in cancer research: it was the first human leukemia cell line ever established, derived in 1970 by Lozzio and Lozzio from the pleural effusion of a 53-year-old female patient with chronic myeloid leukemia (CML) in terminal blast crisis. The line carries the defining lesion of CML, the Philadelphia chromosome translocation t(9;22) that generates the BCR-ABL1 e14a2 (p210) fusion tyrosine kinase, and exhibits an undifferentiated, erythroleukemia-like phenotype in suspension culture. K562 cells are characteristically deficient in surface MHC class I molecules, which makes them exquisitely sensitive to natural killer (NK) cell lysis and has turned them into the standard target cell for NK activity assays worldwide. The line is remarkably prolific in the literature, with well over ten thousand published studies, and responds to BCR-ABL1 tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib, anchoring its role in CML drug research.

Fig 1. Longitudinal bioluminescence imaging of intravenously engrafted K562-HLA-G1-Luc leukemia cells, demonstrating systemic leukemia progression and durable tumor control following HLA-G-directed CAR-T therapy. (Anna, François, et al., 2021)

For orthotopic modeling, K562 is introduced into the natural disease compartments of the host. Luciferase-labeled derivatives (K562-luc) are delivered intravenously into sublethally irradiated NSG (NOD-scid IL2rγ^null) mice, typically at inocula of 2–5 × 10⁶ cells, or injected directly into the femoral cavity as a bone marrow-residing model at around 10⁵ cells. Engrafted cells seed spleen, lymph nodes, bone marrow, and liver, with imaging studies showing that K562 produces its strongest bioluminescent signals in lymph nodes, a distribution pattern distinct from other leukemia lines. Whole-animal bioluminescence after D-luciferin administration then reports systemic disease burden longitudinally, enabling therapy response to be quantified days before clinical decline and supporting survival studies that typically run several weeks. The model is the platform of choice for BCR-ABL1-targeted agent evaluation, TKI resistance studies, and adoptive cell therapy programs involving NK or CAR-engineered effectors. Figure 1 depicts the overall architecture of this orthotopic system.

Cell Line Information: K562 / K562-luc

As the prototypical BCR-ABL1-positive CML line, K562 has been characterized exhaustively. The defining attributes of the parent line and its luciferase-tagged derivative are summarized below.

Our Services

Every K562 / K562-luc program run by Alfa Cytology is anchored by verified cell banks, conditioning regimens suited to the chosen host, calibrated imaging schedules, and a terminal package combining organ-level bioluminescence, flow cytometry, and survival statistics.

Workflow of K562 / K562-luc Orthotopic Mouse Model Construction

Standing up a K562 / K562-luc orthotopic leukemia study follows a clear sequence in which cell authentication, host conditioning, route-specific inoculation, and serial imaging each play a defined role. The sequence below reflects the standard execution of this platform.

1. Cell Bank Verification and Expansion: K562 or K562-luc stocks are authenticated by STR profiling and mycoplasma testing, then expanded in suspension culture with regular feeding to preserve logarithmic growth.
2. Luciferase Calibration (K562-luc Only): In vitro signal output per cell is verified, confirming that in vivo photon flux can be interpreted as relative disease burden.
3. Host Conditioning and Randomization: NSG or related immunodeficient mice are randomized by body weight and, where the protocol requires, conditioned with sublethal irradiation to facilitate human cell engraftment under approved animal protocols.
4. Orthotopic Route-Specific Inoculation: A single-cell suspension is delivered by tail-vein injection (commonly 2–5 × 10⁶ cells) to model systemic leukemia, or by intra-femoral injection (~10⁵ cells) to establish a bone marrow-residing tumor that demands effector homing.
5. Engraftment Confirmation: Whole-animal bioluminescence is captured a few days after inoculation, typically after intraperitoneal D-luciferin (150 mg/kg), to verify cell take and establish baseline disease loads.
6. Scheduled Longitudinal Imaging: Mice are imaged on a defined schedule to chart disease progression in vivo, with body weight and clinical condition recorded alongside.
7. Treatment Administration: Test agents or adoptive cell products are dosed per the client’s regimen, with response read out through the next imaging cycles.
8. Endpoint Analysis and Survival Statistics: At humane endpoint, bone marrow, spleen, lymph nodes, and blood are collected for ex vivo imaging, human CD45⁺ engraftment quantification by flow cytometry, and histopathology; survival data are compiled for Kaplan–Meier analysis.

Fig 2. K562 / K562-luc orthotopic mouse model construction workflow.

Case Study-K562 / K562-luc Orthotopic Mouse Model Development

Alfa Cytology has supported preclinical programs on the K562 / K562-luc orthotopic platform for clients evaluating BCR-ABL1 inhibitors, testing adoptive NK and CAR-based approaches, and probing graft-versus-leukemia mechanisms, delivering longitudinal bioluminescence curves, human engraftment flow data, and survival analyses. As each program is tailored to the client’s therapeutic concept, detailed study outlines and representative datasets are shared upon request.

Why Choose Alfa Cytology?

K562 / K562-luc orthotopic studies succeed or fail on small details: a drifted cell bank, an off-schedule imaging session, or a poorly conditioned host can distort the entire dataset. Alfa Cytology’s controls keep each variable in line so that the biology, not the logistics, drives the results.

• Authenticated K562 / K562-luc banks with STR and mycoplasma verification before any in vivo work.
• Route flexibility covering intravenous systemic, intra-femoral bone marrow-residing, and subcutaneous solid formats.
• Calibrated in-house bioluminescence imaging for quantitative, longitudinal disease monitoring.
• Conditioning regimens matched to the immunodeficient host and the client’s engraftment targets.
• Endpoint flow cytometry, ex vivo organ imaging, and histopathology consolidated into one package.
• Experience across TKI evaluation, adoptive cell therapy, and graft-versus-leukemia study designs.

Contact Us

From BCR-ABL1 inhibitor programs to next-generation NK cell strategies, Alfa Cytology can configure a K562 / K562-luc orthotopic study that answers your specific preclinical question. Contact us today to align on study design, dosing schedule, and imaging cadence, or reach out to our scientific team for a customized quotation.

For research use only. Not intended for any clinical use.